Kedudukan dalam Saham
#23616
MaaT Pharma SA operates as a clinical-stage biotechnology company, focused on... MaaT Pharma SA operates as a clinical-stage biotechnology company, focused on the discovery and advancement of microbiome-based biotherapies, primarily for the treatment of solid cancer tumors. Its development pipeline features MaaT013, which has successfully completed Phase 2 clinical trials for acute graft-versus-host disease (aGVHD) and is also undergoing preclinical evaluation for melanoma. Another therapeutic candidate, MaaT033, is currently in Phase 1b clinical trials, aiming to improve survival outcomes for patients with acute myeloid leukemia (AML) or other liquid malignancies following allogeneic hematopoietic stem cell transplantation. Furthermore, MaaT03X is being developed specifically for solid tumor applications. The company was founded in 2014 and maintains its headquarters in Lyon, France.
Harga Saham
$3.78
Disegerakkan terakhir: 2026-08-21
Perubahan (1 tahun)
-43.37%
Perdagangan MaaT Pharma S.A. (MAAT)
Harga MAAT dengan permodalan pasaran b
Modal pasaran bagi MaaT Pharma S.A.(MAAT)
Modal Pasaran: $71.20M
Sehingga August 2026, MaaT Pharma S.A. mempunyai modal pasaran sebanyak $71.20M. Ini menjadikan MaaT Pharma S.A. syarikat ke-23616th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran MaaT Pharma S.A. dari 2021 hingga 2026
MAAT berbanding dengan 5 teratas yang paling popular stocks
| Harga MAAT |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.211T
|
+7,318,865.32%
|
|
|
|
|
$4.547T
|
+6,385,453.75%
|
|
|
|
|
$4.162T
|
+5,845,776.17%
|
|
|
|
|
$3.593T
|
+5,045,697.23%
|
|
|
|
|
$2.793T
|
+3,922,248.30%
|
